Fluoguide Q2: A broadening pipeline - Redeye

Redeye comments on Fluoguide’s Q2 2022 report, and we judge that the company is laser-focused on delivering catalysts that will bring FG001 into the limelight in the coming six to 12 months. Further, the company provided a general update on FG001’s clinical development timeline and announced head and neck cancer as a new indication. We fine-tune our estimates.

Länk till analysen i sin helhet: https://www.redeye.se/research/853464/fluoguide-q2-2022-a-broadening-pipeline?utm_source=finwire&utm_medium=RSS